Related Experiment Video

Updated: Mar 13, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.5K

Alectinib for treatment of ALK-positive non-small-cell lung cancer

Virginie Avrillon1, Maurice Pérol1

  • 1Department of Medical Oncology, Léon Bérard Cancer Center, Lyon, France.

Future Oncology (London, England)
|October 27, 2016
PubMed

Insights

Alectinib shows superior progression-free survival compared to crizotinib in ALK-positive non-small-cell lung cancer (NSCLC). This positions alectinib as a potential frontline treatment for ALK-positive NSCLC patients.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Alectinib is a second-generation ALK inhibitor effective against crizotinib resistance mutations.
  • It demonstrates good central nervous system penetration and a favorable safety profile.

Purpose of the Study:

  • To review therapeutic options for ALK-positive advanced non-small-cell lung cancer (NSCLC).
  • To summarize the chemical, pharmacodynamic, pharmacokinetic, metabolic, and clinical efficacy data of alectinib.

Main Methods:

  • Review of Phase II and Phase III clinical trial data, including J-ALEX and expected ALEX study results.
  • Analysis of preclinical and clinical data on alectinib's properties.

Main Results:

  • Alectinib is approved for pretreated ALK-positive NSCLC patients in Japan and by the US FDA.
  • The Phase III J-ALEX study demonstrated alectinib's superiority over crizotinib in progression-free survival for crizotinib-naive patients.

Conclusions:

  • Alectinib exhibits significant efficacy and a good safety profile in ALK-positive NSCLC.
  • Results suggest alectinib may become a preferred frontline therapy for ALK-positive NSCLC.
Keywords:
ALKNSCLCalectinibcrizotinibresistance mechanisms

More Related Videos

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

11.1K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.8K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
615